NovoCure Stock Forecast
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 14.35 +0.91%
NVCR analyst consensus
Consensus (7 analysts)
buy
Avg. price target
$26.86+88.89%
- Strong buy 1
- Buy 3
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering NovoCure (2026-10-07), 4 rate the stock a buy or strong buy, 3 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $26.86, with a high estimate of $52.00 and a low estimate of $17.00. The average target implies upside of 88.9% from the current price of $14.22.
The spread between the highest and lowest targets is 205.9%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NVCR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 3 | 43% |
| Hold | 3 | 43% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $17.00 | +19.55% |
| Average target | $26.86 | +88.89% |
| High target | $52.00 | +265.68% |